Showing posts with label patient retention. Show all posts
Showing posts with label patient retention. Show all posts

Wednesday, July 2, 2014

CAHG at DIA


The recent DIA 50th Annual Meeting in San Diego provided an excellent forum for learning about current trends in clinical research. As an exhibitor at the conference, we were afforded a great opportunity to engage with the drug development community and share patient recruitment best practices. The various sessions offered valuable insights from sponsors, CROs, and other vendors, who help comprise the key stakeholders in clinical research.

Some sessions of note attended by the CAHG team during the conference included:

·         A presentation on social listening by Melissa Mottolo of Genentech.

o   Our insight: Social listening is one valuable way to tap into patient sentiments that can help inform how to recruit for a research study. There is still a lot of work to do, even within sponsors with dedicated patient recruitment teams, to show the value of this intelligence gathering tactic.

·         A case study around a new patient social media platform, MyHealthTeams, by Eric Peacock.

o   Our insight: One critical important question about online patient communities is whether they will be primarily used for collaboration and research (in the Patients Like Me model), or whether patients are more interested in support and empathy (more the model of myHealthTeams). Both approaches may be needed to fully reach and engage the maximum number of patients.

·         Presentations on the new breed of online patient communities from Inspire CEO Brian Loew.

o   Our insight: Dedicated online communities are still small, but growing. Not all patients will be comfortable discussing their condition online – even anonymously – but it will be important to measure how these active “hand-raisers” can influence other patients, even those outside the community.

I was happy to have the opportunity to again chair a session on pediatric patient recruitment that started a conversation around best practices for engaging parents about their children participating in clinical trials. Drs. Sue Tansey from Premier Research and Larry Eichenfield from Rady Children’s Hospital also presented during the session and provided invaluable insights from the CRO and site perspective. Dr. Tansey did an excellent job of highlighting research alliance groups working in both Europe and the US to engage parents about pediatric studies, while Dr. Eichenfield expertly related how a busy site is able excel by using a myriad of tactics to build awareness for trials in the local community. Both speakers sparked conversations with the numerous session attendees that will surely keep the discussion of this important topic moving forward beyond San Diego.


Overall, the DIA Annual Meeting was a fabulous platform for meeting other members of the pharmaceutical research industry and engaging in valuable discussions on how to move the industry forward in the coming years and beyond. We are already looking forward to next year’s meeting in Washington, DC!

Tuesday, June 17, 2014

Guest Blog Post Up: First Patient In Welcomes Our Survey Verification Center Guru!

Every once in awhile, the CAHG Clinical Trials group has the good fortune to welcome a guest blogger from our talented team at CAHG. Today we welcome Joe Mason, Assistant Manager of the Survey Verification Center at CAHG!

Joe has participated in data collection for one of CAHG Clinical Trials' observational registries since the project's inception almost 8 years ago, and now plays a lead role in patient retention and data quality assurance for the registry. Not just a data lover, Joe keeps busy leading karaoke nights and playing the theremin in his free time.

Please read on as Joe shares his experience with our nonresponder search process for an observational registry.

Wednesday, June 11, 2014

Celebrate 50 Years of DIA with CAHG in San Diego


Join CAHG next month in San Diego as we celebrate 50 years of DIA.

The DIA Annual Meeting brings together over 7,000 drug development industry professionals from around the globe to discuss pressing issues facing the industry over four days of educational sessions and networking opportunities. The 2014 meeting will be held at the San Diego Convention Center from June 15-19

Like DIA, CAHG brings over 50 years of experience in the pharmaceutical industry, with a deep and rich tradition of excellence across the entire spectrum of drug development. We pride ourselves on innovation and unmatched creativity in our patient recruitment campaigns and other work that sets us apart from our competitors.

If you will be attending the conference, please stop by the CAHG booth (326) to discuss your enrollment needs with our patient recruitment strategists. Or, feel free to pop in and load up on all of the goodies we will have on hand, including a raffle items and other surprises (We know your kids will be clamoring for your flashlights, pens, and other swag when you get home!).


Our goal for the meeting is to share our insights and vision with other meeting attendees in an effort to fortify another 50 years of collaboration under the banner of DIA. We hope to see you there!

Wednesday, May 28, 2014

Parents as Partners - A Pediatric Patient Recruitment Session at the Upcoming DIA Annual Meeting



If you have ever struggled with patient recruitment for a pediatric study, Parents as Partners: Overcoming Unique Challenges to Pediatric Recruitment and Retention, a session at the upcoming DIA 50th Annual Meeting in San Diego is a presentation that is not to be missed.

The session will highlight many of the challenges sponsors and CROs face when trying to recruit and retain patients for these unique studies, while offering suggestions on how to overcome these challenges from a variety of different perspectives.

Watch the preview video above for more information about the session, including a review of the goals and details on the impressive lineup of speakers that will be participating.

See you in San Diego!

If you can’t attend the session in person, please feel free to contact me to discuss the presentation in more detail and answer any questions you may have about pediatric trial recruitment. 

Monday, May 19, 2014

The Importance of Post-Study Recruitment Reporting and Analyses




There is a common trend in clinical research patient recruitment to tout the next big thing or widget that will most certainly help a sponsor fully enroll their next study on-time and budget. While it is certainly worthwhile to try and find new approaches to improve enrollment rates, I have found that it is prudent to pay more attention to basic principles in crafting a cohesive recruitment strategy for your trial.

While many studies and vendors at least pay lip service to the practice of collecting metrics during a recruitment campaign, the number of studies where this data is properly analyzed is relatively small. The rationale for this assertion is certainly anecdotal, but plausible in part because of the number of times that I have seen a sponsor or CRO communicate actionable intelligence from a previous study (maybe three times in ten years).

There are several steps you can take to ensure that your study is set up to produce actionable lessons learned at the end of enrollment:


      Design a data capture infrastructure to collect key metrics in advance of study launch

This seems intuitive enough, but often recruitment metrics are not planned far enough in advance to accommodate any special considerations for a specific study.  If you are relying solely on site-based reporting to measure the success of any initiatives, then it is vital to try and standardize your metrics to some degree up front. Otherwise, you may be stuck trying to aggregate varying levels of data between your sites.

For instance, some sites will precisely record every minor detail in the patient engagement process on a spreadsheet or other database, from first contact, the numbers of times they have followed up with the contact, to any appointment no-shows. Some sites, on the other hand, will be less exact with how they record this information. It is important to make sure you know what metrics you want to capture and communicate the expectations to all sites before FPFV.

Even if you are employing a CRO or patient recruitment vendor to capture data for a centralized campaign, it is still a good idea to finalize what they will be measuring and how in advance of study launch. These organizations often have template systems in place that capture the same metrics for every campaign they support. Be sure to ask about this up front and ensure that their metrics platforms meet your needs.

Ensure that reporting begins early and often in the recruitment campaign

It is a good idea to set the standards for reporting early before the study begins, as well. Most studies have regular check-in meetings between sponsor and vendor and/or sites. Use these discussions as an opportunity to create a reporting interval where current recruitment data can be shared and analyzed by the team. These forums can also be a valuable way to dig deeper into the data by generating regular reports that will allow you to make course corrections to enrollment strategy, if needed.

There are a number of ways to accomplish this within the confines of a study. It all depends on what your data requirements are. Perhaps you want to keep close tabs on cost per referral or screening. Or maybe you are curious about the relationship between site communication (eBlast, phone call, etc.) and screening activity. These are all things that can be measured and reported on throughout enrollment if planned for.

Don’t be afraid to call more frequent meetings or create reports outside of the normal schedule if it will benefit enrollment by prompting timely strategy decision-making. Your enrollment campaign should not be created in a vacuum. Use metrics and reporting to inform how you spend your recruitment dollars.




Insist on a robust final analysis meeting

On more than one occasion, I have encountered objections from key study leaders about the need or benefit of a final analysis meeting.

But why have one in the first place?

Even if recruitment goes exceedingly well for a study, any final analysis should be able to determine some lessons learned from a recruitment campaign, if the right metrics were captured from the beginning. Whether you are a project manager at a sponsor, CRO, site or recruitment vendor, the end of enrollment for any study should include a thorough review of every action that took place in trying to recruit patients to the trial, in an effort to improve those efforts in future campaigns.

Invariably, there will be naysayers who might decry the need for a long meeting to review reports and discuss lessons learned. Ignore these detractors and insist on conducting a thorough final analysis meeting. It will be time well-spent.

Deliver a thorough after-action report, including any key learnings from the final analysis meeting

At the end of any meeting, it is supremely important to recap the discussion and highlight any pertinent action items that were flagged. Once all key learnings are catalogued, a final report should be compiled, including any and all data and takeaways, for distribution to the entire team. If you are talking about a Phase II trial, the report should detail how these learnings can be applied to the next trial. If there are no further studies to leverage, then you should go the extra mile to apply the lessons learned to a therapeutic area or similar type of study where appropriate.


Paying close attention to metrics and reporting is not quite as sexy and cutting edge as touting the latest new trends in patient recruitment. And yet, all too often, data is overlooked or not emphasized enough when developing strategy for completing enrollment on time. If used effectively, reporting can be a way to build rapport and engage the entire study team that will benefit your entire clinical operations infrastructure.

Wednesday, April 16, 2014

Retention Metrics, Simplified

In my experience, most clinical trials do not suffer from significant retention issues. This is a testament to the collaborative good will of most patients who consent to participate, and to the patient-first attitude of most research coordinators.

However, in many trials – especially those that last more than a year – the question of whether there is a retention issue will come up at some point while the trial’s still going. This is often associated with a jump in early terminations, which can occur as the first cohort of enrollees has been in the trial for a while.

It’s a good question to ask midstream: are we on course to have as many patients fully complete the trial as we’d originally anticipated?

However, the way we go about answering the question is often flawed and confusing. Here’s an example: a sponsor came to us with what they thought was a higher rate of early terminations than expected. The main problem? They weren't actually sure.

Here’s their data. Can you tell?


If you can, please let me know how! While this chart is remarkably ... full of numbers, it provides no actual insight into when patients are dropping out, and no way that I can tell to project eventual total retention.

In addition, measuring the “retention rate” as a simple ratio of active to terminated patients will not provide an accurate benchmark until the trial is almost over. Here's why: patients tend to drop out later in a trial, so as long as you’re enrolling new patients, your retention rate will be artificially high. When enrollment ends, your retention rate will appear to drop rapidly – but this is only because of the artificial lift you had earlier.

In fact, that was exactly the problem the sponsor had: when enrollment ended, the retention rate started dropping. It’s good to be concerned, but it’s also important to know how to answer the question.

Fortunately, there is a very simple way to get a clear answer in most cases – one that’s probably already in use by your  biostats team around the corner: the Kaplan-Meier “survival” curve.

Here is the same study data, but patient retention is simply depicted as a K-M graph. The key difference is that instead of calendar dates, we used the relative measure of time in the trial for each patient. That way we can easily spot where the trends are.


In this case, we were able to establish quickly that patient drop-outs were increasing at a relatively small constant rate, with a higher percentage of drops coinciding with the one-year study visit. Most importantly, we were able to very accurately predict the eventual number of patients who would complete the trial. And it only took one graph!